Home > Oncology > ASCO 2019 > Lung Cancer > Pembrolizumab monotherapy leads to 5-year survival in some patients with NSCLC

Pembrolizumab monotherapy leads to 5-year survival in some patients with NSCLC

Presented By
Dr Edward B. Garon, David Geffen School of Medicine, USA
Conference
ASCO 2019
Trial
Phase 1, KEYNOTE-001
Medical writer: Jasenka Piljac Žegarac, PhD Pembrolizumab monotherapy induces a durable anti-tumour response in patients with advanced non–small cell lung cancer (NSCLC), according to 5-year data from KEYNOTE-001—the first clinical trial evaluating pembrolizumab in advanced NSCLC (Abstract LBA9015). “This is the longest follow-up for a large population of treatment-naive and previously treated patients with NSCLC treated with an inhibitor of the PD-1 immune checkpoint,” lead author Edward B. Garon, MD, MS, of the David Geffen School of Medicine, University of California/TRIO-US Network, said. “Not only were we able to induce durable responses, but now we have 5-year follow-up for this patient population.” KEYNOTE-001 is a phase Ib, randomized, open-label study evaluating pembrolizumab in several different types of locally advanced or metastatic cancers. Cohorts C and F aimed to assess the safety, tolerability, and efficacy of pembrolizumab in patient...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on